Cue Biopharma, Inc.
Cue Biopharma, Inc. is listed today as Cue Biopharma, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2026 | $50 M | Private placement after listing | $50 to $250 million | equity, options | SEC | |
| May 2026 | $30 M | Private placement after listing | $10 to $50 million | options | SEC | |
| Nov 2022 | $30 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Dec 2016 | $16 M | No. 2 | $10 to $50 million | equity | SEC | |
| Jun 2015 | $10 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Cue Biopharma, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2026).
SEC Form D · Jul 2026
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jul 2026
That is all the official record says: Cue Biopharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Cue Biopharma, Inc. are on record.
Investors#
No investor of Cue Biopharma, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 133 investors.
Largest shareholders today
Institutions holding Cue Biopharma, Inc. shares, as of Sep 30, 2026.
- Ameriprise Financial Inc$17 M9.09%
- Cormorant Asset Management, LP$16 M8.61%
- Balyasny Asset Management L.P.$11 M5.88%
- Bleichroeder LP$9 M5.04%
- Vanguard Capital Management LLC$8 M4.27%
- Driehaus Capital Management LLC$8 M4.02%
- Ikarian Capital, LLC$8 M4.00%
- Vivo Capital, LLC$7 M3.86%
- Morgan Stanley$5 M2.81%
- Adage Capital Partners GP, L.L.C.$5 M2.75%
- UBS Group AG$3 M1.53%
- Stempoint Capital LP$3 M1.50%
- Nantahala Capital Management, LLC$2 M1.32%
- Boothbay Fund Management, LLC$2 M1.20%
- Geode Capital Management, LLC$2 M0.95%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Dominic Borie | Executive officer | Jul 2026 |
| Michael Meluzio | Executive officer | Jul 2026 |
| Shao-Lee Lin | Executive officer | Jul 2026 |
| Sumita Ray | Executive officer | Jul 2026 |
| Colin Sandercock | Executive officer | May 2026 |
| Daniel Baker | Executive officer | May 2026 |
| Anish R. Suri | Executive officer | Nov 2022 |
| Colin G. Sandercock | Executive officer | Nov 2022 |
| Daniel R. Passeri | Executive officer | Nov 2022 |
| Ken R. Pienta | Executive officer | Nov 2022 |
| Kerri-Ann R. Millar | Executive officer | Nov 2022 |
| Patricia R. Nasshorn | Executive officer | Nov 2022 |
| Daniel Passeri | Chief Executive Officer | Dec 2016 |
| Gary Schuman | Chief Financial Officer | Dec 2016 |
| Rodolfo Chaparro | Vice President, Head of Immunology | Dec 2016 |
| Ronald Seidel Iii | Executive Vice President, Head of Research and Development | Dec 2016 |
| Amy Wang | Secretary | Jun 2015 |
| Cameron Gray | Chief Executive Officer and President | Jun 2015 |
| Ronald Seidel III | Executive Vice President, Head of Research and Development | Jun 2015 |
| Steven Almo | Chairman of Scientific Advisory Board | Jun 2015 |
| Daniel Camardo | Director | Jul 2026 |
| Pamela Garzone | Director | Jul 2026 |
| Pasha Sarraf | Director | Jul 2026 |
| Shao-Lee Lin | Director | Jul 2026 |
| Viola Meehan | Director | Jul 2026 |
| Frank Morich | Director | May 2026 |
| Jill M. Broadfoot | Director | May 2026 |
| Pamela D. Garzone | Director | May 2026 |
| Patrick Verheyen | Director | May 2026 |
| Peter Kiener | Director | May 2026 |
| Aaron G. Fletcher | Director | Nov 2022 |
| Daniel R. Passeri | Director | Nov 2022 |
| Frank G. Morich | Director | Nov 2022 |
| Frederick G. Driscoll | Director | Nov 2022 |
| Peter A. Kiener | Director | Nov 2022 |
| Tamar G. Howson | Director | Nov 2022 |
| Amy Wang | Director | Dec 2016 |
| Anthony Digiandomenico | Director | Dec 2016 |
| Barry Simon | Director | Dec 2016 |
| Cameron Gray | Director | Dec 2016 |
Went public since 2018. Its SEC number is that of a company listed on a stock exchange.